Abstract
Objective: Tralokinumab, administered as two 1-mL subcutaneous injections every 2 weeks, at the target dose 300 mg, has been shown to improve lung fun......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
